UCREST BERHAD (“UCREST” OR “THE COMPANY”) - REPLY TO QUERY FROM BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”) DATED 12 APRIL 2021 PERTAINING TO THE MEMORANDUM OF UNDERSTANDING ("MOU") WITH RUSSIAN DIRECT INVESTMENT FUND ("RDIF") TO IDENTIFY, QUALIFY AND MANAGE THE CONTRACT MANUFACTURERS TO PRODUCE SPUTNIK V ("VACCINES") FOR RDIF ("VENTURE") We refer to the announcement made by the Company dated 9 April 2021 (“Announcement”) and the query by Bursa Securities dated 12 April 2021 (IQL-12042021-00001) in relation to the MOU (“Bursa Query”). Unless otherwise stated, the terms used throughout this announcement shall have the same meanings as defined in the Announcement. We wish to announce the following additional information as required by Bursa Securities pursuant to the Bursa Query:- 1) The duration of the MOU and the date of commencement thereof.
The duration of the MOU will be 6 months or earlier. The commencement date was 9 April 2021
2) Whether the MOU is subject to a definitive agreement to be entered into by UCrest Berhad (“UCrest”) and RDIF.
The definitive agreement will be signed once the detailed arrangements are finalized.
3) To quantify the Vaccines to be purchased by RDIF from UCrest.
Not less than 100 million doses and not more than one billion doses per annum for the first 2 years.
4) To state how UCrest will derive revenue from the contract manufacturing / selling of the Vaccines to RDIF.
RDIF will purchase the vaccines from UCrest and UCrest will be outsourcing the production to manufacturing partners
5) The total capital and investment outlay required to be committed by UCrest in connection with the Venture, the source(s) of funding and the breakdown thereof.
There is no capital expense or investment required. 6) The relevant regulatory approvals, permits and/or licenses required to be obtained in order for UCrest to perform its responsibilities under the MOU. To also state whether UCrest has secured any of these regulatory approvals, permits and/or licences, and the relevant dates of application and approval
There is no regulatory approval, permit or license required from Malaysia authorities for UCrest to perform its responsibilities under the MOU.
7) UCrest’s future plans and prospects in connection with the collaboration with RDIF on the Vaccines.
The future plans and prospects in connection with the collaboration with RDIF on the vaccines is unlimited and will be discussed and negotiated in due course.
8) To elaborate on the financial risk and production risk associated with the MOU.
There are no foreseeable significant risks other than financial risk (ie currency exchange) and production risk (insufficient manufacturing capacity that may refrain UCrest from fulfilling the minimum requirement in a timely manner) associated with the MOU.
Sputnik vaccine bundle with imedic..can monitor patient vital stats and any complication immediately . Link to doc thru cloud. Any side effects and emergency can be traced,monitored ,recorded and followed up.Alarm can be set on imedic to notify doc on any alarming vital signs.
Rdif can get immediate data on vaccine user and do follow up. Cdc issued warning and want all vaccine provider to do close follow up on post vaccination . Rdif is doing that now thru imedic.
Duopharma can do? Bintai can do? Solution can do?
Malaysia gomen shld implement imedic on all covid patient and vaccine user for better healthcare management.
i dare not playing fool with this taiko Ucrest, will support this taiko for at least 2 years andwi ll always stay by side even though like seating roller coaster.
Let the musical chair game begin. At least 6 months to play... (Still can even extend MOU at last minutes) It all depends on how operator want to play it
No more reposted video. U miss it then sorry. Already give early notice many times. Those who saw will buy tomolow. Those who miss will continue to be skeptical . See u at rm 3 in 3 to 6 mths time. 10 to 20 bagger for 2021. Ucrest and keyasic super darkhorse.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
graphic
54 posts
Posted by graphic > 2021-04-14 19:43 | Report Abuse
Tp50